Lipid News

The state of the lipid research community — improving grant review

Binks Wattenberg
March 1, 2018

I have just returned from Washington, D.C., where I was on a National Institutes of Health study section. I am happy to report that the state of the lipid research community is excellent. But it always can be better, particularly when getting our grants reviewed, and that is a prime focus of the American Society for Biochemistry and Molecular Biology’s Lipid Research Division, or LRD.

National Institutes of Health study sessions meet at the main NIH campus in Bethesda, Maryland, shown in this aerial photo.NIH photo

The underlying premise of a new LRD initiative is that grants with a lipid focus suffer when study sections do not have sufficient lipid-centric reviewers. Although the scientific review officers, or SROs, work to get relevant expertise on the panels, several have told me they sometimes struggle to find lipid reviewers. We need individuals on these panels who can put the lipid work into context for the other study section members. Toward this end, we have an ongoing effort to improve the review of lipid-related grants by identifying qualified reviewers with lipid expertise. This has been a three-phase effort.

First, early last year we reached out to the ASBMB membership to encourage members involved in lipid research to join the LRD if they had not done so already. This has swelled the ranks of the division, and we are now 640 members strong.

The second phase was a survey sent out to the LRD membership to capture the review experience and research expertise of each member. The response? Not bad, but could be better. Out of the total membership, 348 received the survey. (Why not all? Explanation below.) Of those, we received 143 responses — an outstanding response rate for this kind of survey request. The survey identified 46 individuals who have NIH reviewing experience, which is the strong preference of the SROs, and an additional eight U.S.-based researchers with non-NIH reviewing experience. Those individuals might be recruited by SROs to increase the ranks of reviewers.

In the third phase, the results of the survey, in spreadsheet form, are now being distributed to SROs of study sections that historically have handled grants from the LRD membership. The SROs’ responses have been very enthusiastic. Finding qualified reviewers with the right expertise is one of their most time-consuming challenges. They definitely will use our results.

We know there are more qualified reviewers out there, and the SROs would love to have them serve on their panels. So rather than the usual kvetching around the bar about the terrible review your lipid grant received, here is how you can help. First, if you do lipid research and are not an LRD member, join here. Second, only a little more than half of the LRD membership received the survey, because many of you have asked not to receive e-mails from the ASBMB. We have no way to reach you. Please consider changing this in your profile so we can get in touch.

While the state of our community is strong in many ways, the fate of lipid grants is in your hands, in more ways than one. Help us to help you.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Binks Wattenberg

Binks Wattenberg is a professor in the department of biochemistry and molecular biology at Virginia Commonwealth University and a member of the ASBMB Today editorial advisory board.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Cholesterol regulatory genes predict liver transplant outcomes
Journal News

Cholesterol regulatory genes predict liver transplant outcomes

April 10, 2026

Researchers identify a link between cholesterol-regulating genes and liver transplant success, which could improve donor screening and patient outcomes.

Lipid signatures for a rare neurological disorder
Journal News

Lipid signatures for a rare neurological disorder

April 10, 2026

Researchers find distinct lipid patterns linked to a rare autoimmune neurological disorder, offering hope for effective targeted therapies for patients.

Disease-linked mutations disrupt protein phase behavior
Journal News

Disease-linked mutations disrupt protein phase behavior

April 9, 2026

Researchers find that pathogenic missense mutations are enriched threefold in phrase-separating intrinsically disordered regions of proteins.

The dual role of asprosin in chronic fatty liver disease
Journal News

The dual role of asprosin in chronic fatty liver disease

April 8, 2026

Researchers uncover a hormone called asprosin that may serve as a potential biomarker for the diagnosis of chronic fatty liver disease and monitoring disease progression.

Novel inhibitor targets RAS-driven cancers
Journal News

Novel inhibitor targets RAS-driven cancers

April 7, 2026

Researchers in Louisville identify a small-molecule drug that blocks RALGEF signaling downstream of mutant RAS. The compound suppresses tumor growth with low toxicity, revealing a new therapeutic strategy for RAS-driven malignancies.

Catching tau in the act
Journal News

Catching tau in the act

April 2, 2026

Using a new proximity-labeling approach, researchers reveal how tangles of the brain-associated protein tau may disrupt RNA biology long before neurons die.